Accuray Inc
Accuray Inc (ARAY) Historical Volatility
ARAY's 30 day historical volatility is 151.94%, in the 88th percentile of readings over the past year. This is a high percentile, meaning Accuray Inc shares have swung far more than usual. ARAY's 30 day implied volatility sits at 800.64%, with an IV Rank of 86.90%, leaving IV 648.70 points above historical volatility. This means options are pricing in more movement than the stock has actually delivered, as of Nov 5, 2026.
Read more
Tracking ARAY historical volatility helps you see how much Accuray Inc's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, ARAY's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor ARAY 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.
Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. ARAY's 30 day historical volatility, or ARAY HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing ARAY's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.
Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy System, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems.
Historical Volatility
Historical movement is elevated versus the past year. The stock has been unusually active.
As of Nov 5, 2026
As of Nov 5, 2026
As of Nov 5, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →